Equities

Hbm Holdings Ltd

Hbm Holdings Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.24
  • Today's Change0.01 / 0.81%
  • Shares traded706.00k
  • 1 Year change-18.42%
  • Beta2.0878
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments140172216
Total Receivables, Net65285.55
Total Inventory01.04--
Prepaid expenses3.526.6518
Other current assets, total1.051.460.67
Total current assets210209241
Property, plant & equipment, net4.887.9619
Goodwill, net------
Intangibles, net7.688.178.49
Long term investments5.756.365.84
Note receivable - long term------
Other long term assets00.638.08
Total assets228232282
LIABILITIES
Accounts payable152226
Accrued expenses7.104.278.14
Notes payable/short-term debt000
Current portion long-term debt/capital leases37423.39
Other current liabilities, total4.236.343.53
Total current liabilities647541
Total long term debt294916
Total debt669119
Deferred income tax2.062.201.95
Minority interest(0.36)(0.33)(0.28)
Other liabilities, total14140.36
Total liabilities10813959
SHAREHOLDERS EQUITY
Common stock0.020.020.02
Additional paid-in capital827827822
Retained earnings (accumulated deficit)(700)(726)(590)
Treasury stock - common(9.22)(8.87)(8.12)
Unrealized gain (loss)------
Other equity, total1.770.99(0.85)
Total equity12093223
Total liabilities & shareholders' equity228232282
Total common shares outstanding734736745
Treasury shares - common primary issue343223
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.